GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » FCF Yield %

HCWB (HCW Biologics) FCF Yield % : -141.90 (As of Apr. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, HCW Biologics's Trailing 12-Month Free Cash Flow is $-14.49 Mil, and Market Cap is $10.21 Mil. Therefore, HCW Biologics's FCF Yield % for today is -141.90%.

The historical rank and industry rank for HCW Biologics's FCF Yield % or its related term are showing as below:

HCWB' s FCF Yield % Range Over the Past 10 Years
Min: -171.87   Med: -40.78   Max: -5.02
Current: -141.9


During the past 6 years, the highest FCF Yield % of HCW Biologics was -5.02%. The lowest was -171.87%. And the median was -40.78%.

HCWB's FCF Yield % is ranked worse than
86.11% of 1497 companies
in the Biotechnology industry
Industry Median: -15.53 vs HCWB: -141.90

HCW Biologics's FCF Margin % for the quarter that ended in Dec. 2024 was -746.33%.


HCW Biologics FCF Yield % Historical Data

The historical data trend for HCW Biologics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HCW Biologics FCF Yield % Chart

HCW Biologics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Yield %
Get a 7-Day Free Trial - -13.28 -30.08 -65.07 -72.92

HCW Biologics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -68.99 -22.57 -79.16 -58.09 -59.35

Competitive Comparison of HCW Biologics's FCF Yield %

For the Biotechnology subindustry, HCW Biologics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HCW Biologics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where HCW Biologics's FCF Yield % falls into.


;
;

HCW Biologics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

HCW Biologics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-14.489 / 19.8697401
=-72.92%

HCW Biologics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-2.948 * 4 / 19.8697401
=-59.35%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HCW Biologics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


HCW Biologics FCF Yield % Related Terms

Thank you for viewing the detailed overview of HCW Biologics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


HCW Biologics Business Description

Traded in Other Exchanges
N/A
Address
2929 N Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Executives
Gary M Winer director C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong director, officer: Chief Executive Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam officer: Chief Financial Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers officer: SVP of Business Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene director C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao officer: VP of Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett director 35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode officer: See Remarks C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd. 10 percent owner 16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057